Literature DB >> 12000193

Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense.

Yutaka Hirakura1, Isabel Carreras, Jean D Sipe, Bruce L Kagan.   

Abstract

Serum amyloid A (SAA) is a family of closely related apolipoproteins associated with high density lipoprotein (HDL). Subclasses of SAA isoforms are differentially expressed constitutively and during inflammation. During states of infection or inflammation, levels of HDL bound, acute phase isoforms of SAA rise as much as 1000-fold in the serum, suggesting that it might play a role in host defense. Following recurrent or chronic inflammation, an N-terminal peptide fragment of SAA known as amyloid A (AA) assembles into fibrils causing extensive damage to spleen, liver, and kidney, and rapidly progressing to death. In the present paper, we report the novel finding that a recombinant acute phase isoform variant of human SAA 1.1 (SAAp) readily forms ion-channels in planar lipid bilayer membranes at physiologic concentrations. These channels are voltage-independent, poorly selective, and are relatively long-lived This type of channel would place a severe metabolic strain on various kinds of cells. Expression of human SAA 1.1 in bacteria induces lysis of bacterial cells, while expression of the constitutive isoform (human SAA4) does not. Secondary structural analysis of the SAA isoforms in dicates a strong hydrophobicity of the N-terminal of the acute phase isoform relative to the constitutive SAA4 isoform, which may be responsible for the bactericidal activity of the former, in keeping with the notion that SAA 1 targets cell membranes and forms channels in them. Channel formation may thus be related to a host defense role of acute phase SAA isoforms and may also be the mechanism of end organ damage in AA and other amyloidoses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000193     DOI: 10.3109/13506120209072440

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  39 in total

1.  Cellular mechanism of fibril formation from serum amyloid A1 protein.

Authors:  Stephanie Claus; Katrin Meinhardt; Tobias Aumüller; Ioana Puscalau-Girtu; Julia Linder; Christian Haupt; Paul Walther; Tatiana Syrovets; Thomas Simmet; Marcus Fändrich
Journal:  EMBO Rep       Date:  2017-06-21       Impact factor: 8.807

2.  Amyloid ion channels: a common structural link for protein-misfolding disease.

Authors:  Arjan Quist; Ivo Doudevski; Hai Lin; Rushana Azimova; Douglas Ng; Blas Frangione; Bruce Kagan; Jorge Ghiso; Ratnesh Lal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-14       Impact factor: 11.205

Review 3.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

Review 4.  Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs.

Authors:  Hyunbum Jang; Fernando Teran Arce; Srinivasan Ramachandran; Bruce L Kagan; Ratnesh Lal; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

5.  Identification of lipopolysaccharide-binding proteins in porcine milk.

Authors:  Farshid Shahriar; John R Gordon; Elemir Simko
Journal:  Can J Vet Res       Date:  2006-10       Impact factor: 1.310

6.  Antifungal Activity of Mammalian Serum Amyloid A1 against Candida albicans.

Authors:  Jiao Gong; Jun Wu; Melanie Ikeh; Li Tao; Yulong Zhang; Jian Bing; Clarissa J Nobile; Guanghua Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 7.  Antimicrobial properties of amyloid peptides.

Authors:  Bruce L Kagan; Hyunbum Jang; Ricardo Capone; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Ruth Nussinov
Journal:  Mol Pharm       Date:  2011-11-29       Impact factor: 4.939

8.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

Review 9.  Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Authors:  Hyunbum Jang; Laura Connelly; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Bruce L Kagan; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2013-02-28       Impact factor: 3.676

Review 10.  The cytokine-serum amyloid A-chemokine network.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Paul Proost; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.